• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Gastroenterology

HLA-DRB1*07:01 confirmed as risk factor for lapatinib-induced liver damage

byMonica ParksandAndrew Bishara
April 4, 2014
in Gastroenterology, Genetics, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD

1. HLA-DRB1*07:01 and HLA-DQA1*02:01 are strongly associated with liver injury among patients with HER2+ primary breast cancer taking lapatinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Lapatinib, a dual HER2/neu and EGFR inhibitor, is used as part of combination therapy for advanced or metastatic HER2-expressing breast cancer. Though previously well-tolerated, it has recently been associated with liver injury. Four human leukocyte antigen (HLA) variants associated with liver injury have been identified using data from previous trials. The purpose of this study was to validate these associations using data from a prospective randomized trial of lapatinib monotherapy (TEACH trial). At the conclusion of this trial, the authors found that the previously identified HLA alleles were strongly associated with liver injury among patients treated with lapatinib. The strongest association was found between ALT elevations and HLA-DRB1*07:01 and HLA-DQA1*02:01. Based on these results, the authors suggest that HLA testing may be used to identify patients at risk for liver injury prior to starting lapatinib. This conclusion is strengthened by the prospective, randomized design of the study and large number of patients included. It should be noted that the original TEACH trial suggested only marginal benefit with lapatinib for disease-free survival in this population, complicating the final interpretation of this study.

Click to read the study in JCO

Relevant Reading: Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomized, controlled, phase 3 trial

In-Depth [prospective randomized controlled trial]: The authors used data from the TEACH trial, a large randomized controlled trial of lapatinib monotherapy with women with HER2+ breast cancer. To assess liver injury, ALT, AST, total bilirubin, and alkaline phosphatase values were collected every 3 months to every 6 weeks throughout the trial, which ran from 2006 to 2009. Genotyping was done to assess the presence of alleles HLA-DRB1*07:01, HLA-DQA1*02:01, HLA-DQB1*02:02 and TNXBrs12153855. A total of 1194 women from the lapatinib arm of the TEACH trial, representing 76% of all women in the treatment arm, were included. Cases were broadly defined as ALT elevation 3 times the upper limit of normal (ULN), and controls those without. The authors found that carriers of the four major histocompatibility complex (MHC) variants were at increased risk for ALT elevation (odds ratio 14). The overall risk of grade 3 ALT elevation was 2.1%, with 7.7% risk among HLA carriers and risk reduction by 0.5% among noncarriers, a similar rate to the placebo arm of the TEACH trial.

RELATED REPORTS

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Early-life body size not an independent risk factor for colorectal cancer

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. 

Tags: Breast CancerchemotherapyEGFR inhibitorgeneticsHER2/neuLapatinibLiver injuryoncologyside-effectsTEACH trial
Previous Post

Systemic beta-blockers and nitrates linked to lower intraocular pressure

Next Post

High hepatitis B antigen predicts hepatic cancer recurrence

RelatedReports

Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia

January 27, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Early-life body size not an independent risk factor for colorectal cancer

January 11, 2023
No benefit of erlotinib in combined hepatocellular carcinoma treatment
Oncology

Spiritual care reduces fatigue and pain among patients receiving chemotherapy

January 11, 2023
Next Post
High hepatitis B antigen predicts hepatic cancer recurrence

High hepatitis B antigen predicts hepatic cancer recurrence

MRI helps predict risk of local recurrence in upper rectal cancers

Educational sessions as effective as physiotherapy for chronic whiplash pain [PROMISE trial]

Single-site robotic cholecystectomy is safe, but technically challenging

In elderly, robotic surgery for endometrial cancer linked with lower morbidity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • 2 Minute Medicine Rewind January 23, 2023
  • Disposable elevator cap duodenoscopes may reduce contamination in endoscopic retrograde cholangiopancreatography – the ICECAP trial
  • Higher body mass index may be associated with altered vitamin D levels and metabolism
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options